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prevalence rates in different populations were weighted to esti-
mate the 2002 annual schizophrenia prevalence in the general
US population. RESULTS: The annual prevalence rate of schiz-
ophrenia in the US in 2002 was estimated at 0.5%. The Medic-
aid population was identiﬁed as having the highest schizophrenia
prevalence rate in the US (1.7% for non-Medicare dual eligible
enrollees), whereas annual schizophrenia prevalence rates in
Medicare and privately insured population were 0.7% and
0.1%, respectively. The disease was also more prevalent in the
uninsured population (1.1%). CONCLUSIONS: The results
suggest that schizophrenia may be more prevalent in the US
general population than previously estimated in some epidemi-
ology survey studies, especially given the fact that claims data-
base analyses usually provide lower bounds of prevalence
estimates. Schizophrenia is most prevalent in the low income and
uninsured populations than in the privately insured or Medicare
populations. Given the high cost of the disease, efforts should be
made to reach patients in these populations to deliver appropri-
ate treatments.
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OBJECTIVE: To investigate the impact of inpatient versus out-
patient treatment of schizophrenia on psychiatric hospital pro-
ﬁtability in Japan. This is a timely investigation because one of
the Japanese Government’s current objectives is to shift treat-
ment of schizophrenic patients from the inpatient to the outpa-
tient setting. METHODS: The investigators accessed schedules
of hospital reimbursement in Japan and met with a group of
Japanese private hospital owners to gain a sound understanding
of costs and income of private psychiatric hospitals. An interac-
tive model was then built which allowed quantiﬁcation and sim-
ulation of proﬁtability of inpatient versus outpatient treatment.
The model will be supplied to hospital owners in Japan so that
they can assess the proﬁtability of different treatment settings for
their hospital. RESULTS: The preliminary analysis using the
model found that revenues were higher if patients were treated
in the inpatient setting, compared with the outpatient setting. In
a typical hospital, approximately 21–24 outpatients are required
to generate a similar income to that earned from treatment of
one inpatient. In order to achieve this, hospitals would be
required to expand their outpatient care capacity and improve
the quality of outpatient care. CONCLUSIONS: Shifting the
treatment of patients from the inpatient to the outpatient setting
will require a signiﬁcant expansion of the current outpatient care
capacity. Further improvement in the quality of outpatient care
will be necessary to attract more patients to compensate for the
revenue loss associated with the shift. The project demonstrates
the complexities of undertaking ﬁnancial analysis in Japan.
While it is possible to conduct such projects, researchers need to
explore a range of data options and consult widely with the
intended user.
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OBJECTIVES: To assess the cost-effectiveness of long-acting
risperidone (LAI-RIS), oral risperidone (RIS), olanzapine (OLA),
quetiapine (QUE), ziprasidone (ZIP), aripiprazole (ARI), and
haloperidol decanoate (HAL-DEC) in patients with schizophre-
nia over one-year from a health care system perspective.
METHODS: Published medical literature, an unpublished con-
sumer health database, and a clinical expert panel were utilized
to populate a decision tree model. The model captured rates of
compliance and relapse, frequency and duration of relapse,
adverse events, resource utilization and unit costs. Outcomes
included percentage, number and duration of relapses per patient
per year and direct medical costs. RESULTS: The mean days of
relapse requiring hospitalization per patient per year were 28
HAL-DEC, 18 RIS, OLA, QUE, ZIP and ARI, 11 LAI-RIS, while
the mean days of exacerbation not requiring hospitalization were
eight HAL-DEC, ﬁve RIS, OLA, QUE, ZIP and ARI, three LAI-
RIS. Direct medical cost savings with LAI-RIS compared to RIS,
OLA, QUE, ZIP, ARI, and HAL-DEC were $161, $1425, $508,
$259, $1068, and $8224, respectively. CONCLUSIONS: Long-
acting risperidone may lead to substantially lower rates and
fewer days of symptom exacerbation and hospitalization com-
pared to currently available treatments. These lower rates trans-
late into direct medical cost savings with the use of long-acting
risperidone.
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OBJECTIVES: To compare the direct annual mental health 
cost and the cost of service components for schizophrenia
patients who relapsed with patients who did not relapse.
METHODS: Data were drawn from a large multi-site three-
year prospective naturalistic study of patients treated for schiz-
ophrenia in the United States, conducted between July, 1997 
and September, 2003. Relapse was deﬁned as psychiatric 
hospitalization, use of emergency services, use of crisis beds, or
suicide attempts. Relapse-related and other service utilization
was based on patients’ medical records and patients’ self-reports,
collected at enrollment and at six-month intervals thereafter.
Costs (charges) were based on the treatment sites’ medical 
information systems. Propensity score adjusted bootstrap re-
sampling was used to compare the total one-year mental 
health cost and cost of service components for patients who
relapsed with those who did not relapse. RESULTS: Patients 
who relapsed (20%, or N = 310/1557) incurred signiﬁcantly
higher mental health cost during the following one-year as com-
pared to patients who did not relapse ($33,296 vs. $11,823 p <
0.01). In addition to higher cost of acute care services (e.g., psy-
chiatric hospitalizations and emergency services), the relapsed
patients also had signiﬁcantly higher cost of day treatment
($1816 vs. $1510, p < 0.01), medication management ($1436
vs. $1125, p < 0.01), outpatient individual therapy ($1987 vs.
$1088, p < 0.01), and case management ($1406 vs. $907, p <
0.01). The cost of all psychotropic medications was numerically
but not statistically higher ($5646 vs. $4611, n.s), reﬂecting 
a numerically higher cost of antipsychotics ($4313 vs. $3636,
n.s), and of other psychotropic agents ($1333 vs. $976, n.s).
CONCLUSIONS: Relapse of patients with schizophrenia is 
associated with substantial direct mental health costs. Findings
highlight the economic impact of relapse and the importance 
